Childress Capital Advisors LLC Has $1.40 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Childress Capital Advisors LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 9,606 shares of the company’s stock after selling 1,059 shares during the period. Childress Capital Advisors LLC’s holdings in Johnson & Johnson were worth $1,404,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Innealta Capital LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $27,000. Christopher J. Hasenberg Inc bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $31,000. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $44,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $43,000. Finally, Grayhawk Investment Strategies Inc. lifted its stake in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. TD Securities cut their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 3rd. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $164.38 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market cap of $395.61 billion, a P/E ratio of 10.25, a PEG ratio of 2.73 and a beta of 0.53. The company has a fifty day moving average price of $157.57 and a 200 day moving average price of $153.81. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the company earned $2.80 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.